Skip to main content
. Author manuscript; available in PMC: 2017 Jul 14.
Published in final edited form as: J Dermatol Sci. 2016 Dec 12;85(3):197–207. doi: 10.1016/j.jdermsci.2016.12.010

Fig. 4.

Fig. 4

The p38 mitogen-activated protein kinase (p38MAPK) inhibitor SB202190 prevented desmoglein 1 (Dsg1) clustering, but not blistering by a mixture of pathogenic and non-pathogenic anti-Dsg1 IgG monoclonal antibodies (mAbs). Human skin specimens were pretreated with the p38MAPK inhibitor SB202190 or DMSO for 1.5 h. Pretreated skins were injected anti-Dsg1 IgG mAbs with SB202190 or DMSO and cultured for 22 h. Histology and immunofluorescence of Dsg1 staining of confocal microscopy were shown. SB202190 had no effect for Dsg1 distribution of individual anti-Dsg1 IgG mAb injected skin. On the other hand, SB202190 blocked the Dsg1 clustering induced by the mixture injection (PF1-8-15 IgG + PF1-2-6 IgG), but could not block blistering caused by PF1-8-15 IgG and the mixture injection. Bar = 20 μm.